AAAAAA

   
Results: 1-25 | 26-31
Results: 1-25/31
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors
Authors: Hartmann, JT Fossa, SD Nichols, CR Droz, JP Horwich, A Gerl, A Beyer, J Pont, J Fizazi, K Hecker, H Kanz, L Einhorn, L Bokemeyer, C
Citation: Jt. Hartmann et al., Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors, J NAT CANC, 93(22), 2001, pp. 1733-1738
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis
Authors: Hartmann, JT Einhorn, L Nichols, CR Droz, JP Horwich, A Gerl, A Fossa, SD Beyer, J Pont, J Schmoll, HJ Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis, J CL ONCOL, 19(6), 2001, pp. 1641-1648
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy-results from an international study group
Authors: Fizazi, K Tjulandin, S Salvioni, R Germa-Lluch, JR Bouzy, J Ragan, D Bokemeyer, C Gerl, A Flechon, A de Bono, JS Stenning, S Horwich, A Pont, J Albers, P De Giorgi, U Bower, M Bulanov, A Pizzocaro, G Aparicio, J Nichols, CR Theodore, C Hartmann, JT Schmoll, HJ Kaye, SB Culine, S Droz, JP Mahe, C
Citation: K. Fizazi et al., Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy-results from an international study group, J CL ONCOL, 19(10), 2001, pp. 2647-2657
Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer
Authors: Rick, O Bokemeyer, C Beyer, J Hartmann, JT Schwella, N Kingreen, D Neureither, S Metzner, B Casper, J Wandt, H Hartmann, F Schmoll, HJ Derigs, G Gerl, A Berdel, WE Kanz, L Siegert, W
Citation: O. Rick et al., Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer, J CL ONCOL, 19(1), 2001, pp. 81-88
Extragonadal seminoma - An international multicenter analysis of prognostic factors and long term treatment outcome
Authors: Bokemeyer, C Droz, JP Horwich, A Gerl, A Fossa, SD Beyer, J Pont, J Schmoll, HJ Kanz, L Einhorn, L Nichols, CR Hartmann, JT
Citation: C. Bokemeyer et al., Extragonadal seminoma - An international multicenter analysis of prognostic factors and long term treatment outcome, CANCER, 91(7), 2001, pp. 1394-1401
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation
Authors: Hartmann, JT von Vangerow, A Fels, LM Knop, S Stolte, H Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation, BR J CANC, 84(3), 2001, pp. 313-320
Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors
Authors: Hartmann, JT Nichols, CR Droz, JP Horwich, A Gerl, A Fossa, SD Beyer, J Pont, J Fizazi, K Einhorn, L Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors, J NAT CANC, 92(1), 2000, pp. 54-61
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors
Authors: Hartmann, JT Knop, S Fels, LM van Vangerow, A Stolte, H Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors, ANTI-CANC D, 11(1), 2000, pp. 1-6
First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases
Authors: Kollmannsberger, C Nichols, C Bamberg, M Hartmann, JT Schleucher, N Beyer, J Schoffski, P Derigs, G Ruther, U Bohlke, I Schmoll, HJ Kanz, L Bokemeyer, C
Citation: C. Kollmannsberger et al., First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases, ANN ONCOL, 11(5), 2000, pp. 553-559
Follow up after primary treatment: curable diseases treated non-surgically
Authors: Bokemeyer, C Kollmannsberger, C Hartmann, JT Kanz, L
Citation: C. Bokemeyer et al., Follow up after primary treatment: curable diseases treated non-surgically, ANN ONCOL, 11, 2000, pp. 73-78
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors
Authors: Bokemeyer, C Hartmann, JT Mayer, F Bohlke, I Kanz, L von Pawel, J Derigs, G Schroder, M
Citation: C. Bokemeyer et al., UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors, ONCOLOGY-NY, 14(10), 2000, pp. 63-67
Comparative study of the acute nephrotoxicity from standard dose cisplatin+/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide
Authors: Hartmann, JT Fels, LM Franzke, A Knop, S Renn, M Maess, B Panagiotou, P Lampe, H Kanz, L Stolte, H Bokemeyer, C
Citation: Jt. Hartmann et al., Comparative study of the acute nephrotoxicity from standard dose cisplatin+/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide, ANTICANC R, 20(5C), 2000, pp. 3767-3773
Phase II study of continuous 120-hour- infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma
Authors: Hartmann, JT Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., Phase II study of continuous 120-hour- infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma, ANTICANC R, 20(2B), 2000, pp. 1177-1182
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors
Authors: Hartmann, JT Fels, LM Knop, S Stolte, H Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors, INV NEW DR, 18(3), 2000, pp. 281-289
Diarrhea and constipation
Authors: Hartmann, JT Bokemeyer, C
Citation: Jt. Hartmann et C. Bokemeyer, Diarrhea and constipation, ANTIB CHEMY, 50, 2000, pp. 184-188
The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors
Authors: Hartmann, JT Nichols, CR Droz, JP Horwich, A Gerl, A Fossa, SD Beyer, J Pont, J Einhorn, L Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors, CANCER, 88(11), 2000, pp. 2629-2635
A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer
Authors: Kollmannsberger, C Quietzsch, D Haag, C Lingenfelser, T Schroeder, M Hartmann, JT Baronius, W Hempel, V Clemens, M Kanz, L Bokemeyer, C
Citation: C. Kollmannsberger et al., A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer, BR J CANC, 83(4), 2000, pp. 458-462
Late toxicity following curative treatment of testicular cancer
Authors: Kollmannsberger, C Kuzcyk, M Mayer, F Hartmann, JT Kanz, L Bokemeyer, C
Citation: C. Kollmannsberger et al., Late toxicity following curative treatment of testicular cancer, SEM SURG ON, 17(4), 1999, pp. 275-281
Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer
Authors: Hartmann, JT Quietzsch, D Daikeler, T Kollmannsberger, C Mayer, F Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer, ANTI-CANC D, 10(8), 1999, pp. 729-733
Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma
Authors: Kollmannsberger, C Brugger, W Hartmann, JT Maurer, F Bohm, P Kanz, L Bokemeyer, C
Citation: C. Kollmannsberger et al., Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma, ANTI-CANC D, 10(5), 1999, pp. 453-456
UFT/calcium folinate plus weekly paclitaxel for solid tumors
Authors: Bokemeyer, C Hartmann, JT Kollmannsberger, C Mayer, F Kanz, L
Citation: C. Bokemeyer et al., UFT/calcium folinate plus weekly paclitaxel for solid tumors, ONCOLOGY-NY, 13(7), 1999, pp. 106-111
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis
Authors: Bokemeyer, C Kollmannsberger, C Meisner, C Harstrick, A Beyer, J Metzner, B Hartmann, JT Schmoll, HL Einhorn, L Kanz, L Nichols, C
Citation: C. Bokemeyer et al., First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis, J CL ONCOL, 17(11), 1999, pp. 3450-3456
Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer
Authors: Hartmann, JT Kuczyk, MA Kollmannsberger, C Kanz, L Bokemeyer, C
Citation: Jt. Hartmann et al., Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer, WORLD J URO, 17(5), 1999, pp. 324-333
Chemotherapy for renal cell carcinoma
Authors: Hartmann, JT Bokemeyer, C
Citation: Jt. Hartmann et C. Bokemeyer, Chemotherapy for renal cell carcinoma, ANTICANC R, 19(2C), 1999, pp. 1541-1543
Treatment of patients with cisplatin-refractory testicular germ-cell cancer
Authors: Bokemeyer, C Kollmannsberger, C Harstrick, A Beyer, J Gerl, A Casper, J Metzner, B Hartmann, JT Schmoll, HJ Kanz, L
Citation: C. Bokemeyer et al., Treatment of patients with cisplatin-refractory testicular germ-cell cancer, INT J CANC, 83(6), 1999, pp. 848-851
Risultati: 1-25 | 26-31